Back to top

Viking catalysts include VK3019, VK2735 readouts in Q3, says Raymond James

Raymond James tells investors in a research note that Viking Therapeutics (VKTX) initiated a Phase 1 single ascending dose study of VK3019, a dual ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viking Therapeutics, Inc. (VKTX)